Skip to main content

Advertisement

SpringerLink
Log in

Curative radiotherapy in patients with anal cancer: clinical outcomes and prognostic factors in a single-institution experience

Risultati clinici e fattori prognostici dopo radioterapia curativa nei pazienti con cancro anale: l’esperienza di una singola istituzione

  • Radiotherapy / Radioterapia
  • Published:
La radiologia medica Aims and scope Submit manuscript

Abstract

Purpose

Our aim was to retrospectively analyse a series of patients with anal cancer treated with curative intent at a single institute in terms of survival and local disease control.

Materials and methods

Forty-two patients with anal cancer were treated with primary radiotherapy with or without concurrent chemotherapy. The influence of the prognostic factors on overall (OS), disease-free (DFS), disease-specific (DSS), colostomy-free (CFS) and metastasis-free (MFS) survival was evaluated.

Results

Nine patients had stage I, 15 stage II, four stage IIIA and 14 stage IIIB disease. Tumour progression/ persistence occurred in five patients (12%). The 5-year OS, DSS, DFS, CFS and MFS were 72.7%, 84.2%, 85.7%, 81.1% and 87.1%, respectively. On univariate analysis, T stage emerged as highly significant for OS, DSS, CFS and DFS, whereas N status was a significant prognostic factor for DSS. On multivariate analysis, T stage was a significant prognostic factor for OS and CFS.

Conclusions

Our data support the view that combined chemoradiation treatment of anal cancer is feasible and may provide survival benefits with an acceptable rate of adverse effects. We should consider T and N stages as important prognostic factors for survival.

Riassunto

Obiettivo

Il nostro obiettivo era quello di analizzare retrospettivamente una serie di pazienti con cancro anale trattati con intento curativo, in termini di sopravvivenza e controllo locale.

Materiali e metodi

Quarantadue pazienti con cancro anale sono stati trattati con radioterapia +/− chemioterapia concomitante. è stato valutato l’impatto dei fattori prognostici su sopravvivenza globale (OS), sopravvivenza libera da malattia (DFS), sopravvivenza specifica di malattia (DSS), sopravvivenza libera da colostomia (CFS) e sopravvivenza libera da metastasi (MFS).

Risultati

Lo stadio di malattia era: 9 pazienti stadio I, 15 pazienti stadio II, 4 pazienti stadio IIIA, e 14 stadio IIIB. La progressione/persistenza di malattia si è verificata in 5 pazienti (12%). I valori di OS, DSS, DFS, CFS, MFS a 5 anni sono stati 72,7%, 84,2%, 85,7% 81,1% e 87,1%, rispettivamente. All’analisi univariata, il T è emerso come fattore prognostico significativo per l’OS, DSS, CFS e DFS, mentre l’N è risultato significativo per la DSS. All’analisi multivariata, il T è risultato un fattore significativo per l’OS e la CFS.

Conclusioni

I nostri dati confermano che la radiochemioterapia nel cancro anale è fattibile e può fornire un beneficio di sopravvivenza con tossicità accettabili. Dovremmo considerare il T e l’N come importanti fattori prognostici per la sopravvivenza.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References/Bibliografia

  1. Johnson LG, Madaleine MM, Newcomer LM et al (2004) Anal cancer incidence and survival: the surveillance epidemiology, and end results experience, 1973–2000. Cancer 101:281–288

    Article  PubMed  Google Scholar 

  2. Jemal A, Siegel R, Ward E et al (2006) Cancer statistics. CA Cancer J Clin 56:106–130

    Article  PubMed  Google Scholar 

  3. Glynne-Jones R, Northover JM, Cervantes A (2010) Anal cancer: ESMO clinical practice guidelines diagnosis, treatment and follow-up. Annals of Oncol 21(Suppl 5):87–92

    Article  Google Scholar 

  4. Salmon RJ, Zafrani B, Labib A et al (1986) Prognosis of cloacogenic and squamous cancers of the anal canal. Dis Colon Rectum 29:336–340

    Article  PubMed  CAS  Google Scholar 

  5. Golden GT, Horsley JS 3rd (1976) Surgical management of epidermoid carcinoma of the anus. Am J Surg 131:275–280

    Article  PubMed  CAS  Google Scholar 

  6. Chao C, Goldberg M, Hoffman JP (2000) Surgical salvage therapy: Abdominoperineal resection for recurrent anal carcinoma, metastasectomy of recurrent colorectal cancer, and esophagectomy after combined chemoradiation. Curr Opin Oncol 12:353–356

    Article  PubMed  CAS  Google Scholar 

  7. Schiller DE, Cummings BJ, Rai S et al (2007) Outcomes of salvage surgery for squamous cell carcinoma of the anal canal. Ann Surg Oncol 14:2780–2789

    Article  PubMed  Google Scholar 

  8. Martin FT, Kavanagh D, Waldron R (2009) Squamous cell carcinoma of the anal canal. Surgeon 7:232–237

    Article  PubMed  CAS  Google Scholar 

  9. Nigro ND, Vaitkevicius VK, Considine B Jr (1974) Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum 17:354–356

    Article  PubMed  CAS  Google Scholar 

  10. Nigro ND, Vaitkevicius VK, Considine B Jr (1977) Combined therapy for cancer of the anal canal: a follow-up report. Dis Colon Rectum 20:677–678

    Article  PubMed  Google Scholar 

  11. UKCCCR Anal Cancer Trial Working Party (1996) Epidermoid anal cancer: results from the UKCCCR randomized trial of radiotherapy alone versus radiotherapy, 5-fluoruracil, and mitomicyn. UK Co-ordinating Committee on Cancer Research. Lancet 348:1049–1054

    Article  Google Scholar 

  12. Flam M, John M, Pajak TF et al (1996) Role of mitomicyn in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 14:2527–2539

    PubMed  CAS  Google Scholar 

  13. Bartelink H, Reolofsen F, Eschwege F et al (1997) Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 15:2040–2049

    PubMed  CAS  Google Scholar 

  14. Radiation Therapy Oncology Group Acute Radiation Morbidity Scoring Criteria. Available at http://www.rtog.org/ResearchAssociates/AdverseEventReporting/AcuteRadiationMorbidityScoringCriteria.aspx. Accessed 13 August 2012

  15. Radiation Therapy Oncology Group Late Radiation Morbidity Scoring Criteria. Available at http://www.rtog.org/ResearchAssociates/AdverseEventReporting/RTOGEORTCLateRadiationMorbidityScoringSchema.aspx. Accessed 13 August 2012

  16. Uronis HE, Bendell JC (2007) Anal cancer: an overview. Oncologist 12:524–534

    Article  PubMed  Google Scholar 

  17. Northover J, Glynne-Jones R, Sebag-Montefiore D et al (2010) Chemoradiation for the treatment of epidermoid anal cancer: 13-years follow up of the first randomized UKCCR Anal Trial (ACT I). Br J Cancer 102:1123–1128

    Article  PubMed  CAS  Google Scholar 

  18. Young SC, Solomon MJ, Hruby G et al (2009) Review of 120 anal cancer patients. Colorectal Dis 11:909–916

    Article  PubMed  CAS  Google Scholar 

  19. Chakravarthy AB, Catalano PJ, Martenson JA et al (2011) Longterm follow-up of a phase II trial of high-dose radiation with concurrent 5-fluorouracil and cisplatin in patients with anal cancer (ECOG E4292). Int J Radiat Oncol Biol Phys 81:e607–e613

    Article  PubMed  CAS  Google Scholar 

  20. Zampino MG, Magni E, Leonardi MC et al (2011) Concurrent cisplatin, continuous infusion fluorouracil and radiotherapy followed by tailored consolidation treatment in non metastatic anal squamous cell carcinoma. BMC Cancer 11:55

    Article  PubMed  CAS  Google Scholar 

  21. Oblak I, Petric P, Anderluh F et al (2009) Anal cancer chemoirradiation with curative intent — a single institution experience. Neoplasma 56:150–155

    Article  PubMed  CAS  Google Scholar 

  22. Salomon RJ, Zafrani B, Labib A et al (1986) Prognosis of cloacogenic and squamous cancer of the anal canal. Dis Colon Rectum 29:336–340

    Article  Google Scholar 

  23. Longo WE, Vernava AM, Wade TP et al (1994) Recurrent squamous cell carcinoma of the anal canal. Predictors of initial treatment failure and results of salvage therapy. Ann Surg 220:40–49

    CAS  Google Scholar 

  24. Das P, Crane CH, Eng C et al (2008) Prognostic factors for squamous cell cancer of the anal canal. Gastrointestinal Cancer Res 2:10–14

    Google Scholar 

  25. Gunderson LL, Winter KA, Ajani JA et al (2006) Intergroup RTOG 9811 phase III comparison of chemoradiation with 5-FU and mitimycin C vs 5-FU and cisplatin for anal canal carcinoma: impact on disease-free, overall and colostomy-free survival. Int J Radiat Oncol Biol Phys 66:S24

    Article  Google Scholar 

  26. Ajani JA, Winter KA, Gunderson LL et al (2006) Intergroup 98-11: a phase III randomized study of 5-fluoruracil (5-FU), mitomycin and radiotherapy vs 5-fluoruracil, cisplatin and radiotherapy in carcinoma of the anal canal. J Clin Oncol 24:180s

    Google Scholar 

  27. Roohipour R, Patil S, Goodman KA et al (2008) Squamous-cell carcinoma of the anal canal: predictors of treatment outcome. Dis Colon Rectum 51:147–153

    Article  PubMed  Google Scholar 

  28. Myerson RJ, Kong F, Birnbaum EH et al (2001) Radiation therapy for epidermoid carcinoma of the anal canal, clinical and treatment factors associated with outcome. Radiother Oncol 61:15–22

    Article  PubMed  CAS  Google Scholar 

  29. Das P, Bhatia S, Eng C et al (2007) Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys 68:794–800

    Article  PubMed  Google Scholar 

  30. Widder J, Kastenberger R, Fercher E et al (2008) Radiation dose associated with local control in advanced anal cancer: retrospective analysis of 129 patients. Radiother Oncol 87:367–375

    Article  PubMed  Google Scholar 

  31. Engineer R, Mallik S, Mahantshetty U et al (2010) Impact of radiation dose on locoregional control and survival on squamous cell carcinoma of anal canal. Radiother Oncol 95:283–287

    Article  PubMed  Google Scholar 

  32. Olivatto LO, Cabral V, Rosa A et al (2011) Mitomycin C-or cisplatin-based chemoradiotherapy for anal canal carcinoma: long-term results. Int J Radiat Oncol Biol Phys 79:490–495

    Article  PubMed  CAS  Google Scholar 

  33. Vuong T, Devic S, Belliveau P et al (2003) Contribution of conformal therapy in the treatment of anal canal carcinoma with combined chemotherapy and radiotherapy: results of a phase II study. Int J Radiat Oncol Biol Phys 56:823–831

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Sant’Andrea Hospital, “La Sapienza” University, Rome, Italy

    M. F. Osti, L. Agolli, C. Scaringi, S. Bracci, G. Minniti & R. Maurizi Enrici

  2. Sant’Andrea Hospital, Via di Grottarossa 1035-1039, 00189, Rome, Italy

    L. Agolli

Authors
  1. M. F. Osti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Agolli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Scaringi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Bracci
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G. Minniti
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R. Maurizi Enrici
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L. Agolli.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Osti, M.F., Agolli, L., Scaringi, C. et al. Curative radiotherapy in patients with anal cancer: clinical outcomes and prognostic factors in a single-institution experience. Radiol med 118, 882–894 (2013). https://doi.org/10.1007/s11547-012-0900-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11547-012-0900-0

Keywords

Parole chiave

Search

Navigation